NCT04290806

Registry Platform Gastric/Esophageal Cancer (SAPHIR)

Clinical Research Platform For Molecular Testing, Treatment, Quality Of Life And Outcome Of Patients With Esophageal, Gastric Or Gastroesophageal Junction Cancer Requiring Palliative Systemic Therapy

• Status: Recruiting
• Phase: —
• Study type: Observational
• Enrollment: 1,900 (estimated)
• Sponsor: iOMEDICO AG · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The registry aims to collect and analyse information on the antineoplastic treatment of patients with metastatic esophageal, gastric or gastroesophageal junction cancer, treated in palliative intention in daily routine practice in Germany.

Detailed description

SAPHIR is a national, observational, prospective, longitudinal, multicenter cohort study (tumor registry platform) with the purpose to record information on the antineoplastic treatment of metastatic esophageal, gastric or gastroesophageal junction Cancer in Germany. The registry will follow patients for up to two years. It will identify common therapeutic sequences and changes in the treatment of the disease. At inclusion, data in patient characteristics, comorbidities, tumor characteristics and previous treatments are collected. During the course of observation data on all systemic treatments, radiotherapies, surgeries, and outcome are documented. Health-related quality of life (HRQoL) will be evaluated for up to two years.

Conditions

• Esophageal Squamous Cell Carcinoma
• Gastric Adenocarcinoma
• Gastroesophageal Junction Adenocarcinoma
• Esophageal Adenocarcinoma

Interventions

Type	Name	Description
OTHER	Routine care as per site standard	Physician's choice according to patient's needs. Routine care as per site standard.

Timeline

• Start date: 2019-12-04
• Primary completion: 2028-12-31
• Completion: 2028-12-31
• First posted: 2020-03-02
• Last updated: 2026-01-28

Locations

1 site across 1 country: Germany